Article
Pharmaceutical Executive
FDA's Breakthrough Designation is Working, Says Report
April 21, 2016.
The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .
Read Jill Wechsler's view in Applied Clinical Trials.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Videos
Related Content
